Current and experimental antibody-based therapeutics: Insights, breakthroughs, setbacks and future directions

Current Molecular Medicine

Volumn 13, Issue 1, 2013, Pages 65-178

  Murad, J P ^a   Lin, O A ^a   Paez Espinosa, E V ^a   Khasawneh, F T ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Antibody; Antibody based therapeutics; Antithrombotic agents; Immune response; Monoclonal antibodies

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; FIBRINOLYTIC AGENT; MONOCLONAL ANTIBODY;

CHEMISTRY; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; IMMUNOTHERAPY; NEOPLASMS;

EID: 84957942752     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: None     Document Type: Article

References (171)

1. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006; 56: 226-43.
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. J Immunol 2005; 174: 2453-5.
3. Abes R, Dutertre CA, Teillaud JL. [Antibodies: better knowledge for a better use]. Med Sci (Paris) 2009; 25: 1011-9.
4. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10: 345-52.
5. Cambrosio A, Keating P. Between fact and technique: the beginnings of hybridoma technology. J Hist Biol 1992; 25: 175-230.
6. Jurcic JG, Scheinberg DA, Houghton AN. Monoclonal antibody therapy of cancer. Cancer Chemother Biol Response Modif 1997; 17: 195-216.
7. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-16.
8. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodiesfor the treatment of cancer. Semin Cancer Biol 2012; 22(1): 3-13.
9. Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 1995; 105: 23-9.
10. Norman DJ. Mechanisms of action and overview of OKT3. Ther Drug Monit 1995; 17: 615-20.
11. Pallardy M. [Toxic effects and use of therapeutic monoclonal antibodies]. Med Sci (Paris) 2009; 25: 1130-4.
12. Zhou H, Mascelli MA. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol 2011; 51: 359-72.
13. Mazzaferri EL Jr, Young JJ. Abciximab: a review and update for clinicians. Expert Rev Cardiovasc Ther 2008; 6: 609-18.
14. Schror K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003; 15: 71-80.
15. Proimos G. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors. J Thromb Thrombolysis 2001; 11: 99-110.
16. McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali DL, Trimpe KL, Carney WP. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 1989; 4: 543-8.
17. Yang J, Ji S, Dong N, Zhao Y, Ruan C. Engineering and characterization of a chimeric anti-platelet glycoprotein Ibalpha monoclonal antibody and preparation of its Fab fragment. Hybridoma (Larchmt) 2010; 29: 125-32.
18. Dincq S, Bosman F, Buyse MA, et al. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway. Protein Expr Purif 2001; 22: 11-24.
19. Lund LN, Gustavsson PE, Michael R, et al. Novel peptideligand with high binding capacity for antibody purification. J Chromatogr A 2012; 1225: 158-67.
20. Yamada T. Therapeutic monoclonal antibodies. Keio J Med2011; 60: 37-46.
21. Tomita M, Tsumoto K. Hybridoma technologies for antibodyproduction. Immunotherapy 2011; 3: 371-80.
22. Di Fede G, Bronte G, Rizzo S, et al. Monoclonal antibodiesand antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. Expert Opin Biol Ther 2011; 11: 1433-45.
23. Seldon TA, Hughes KE, Munster DJ, Chin DY, Jones ML.Improved Protein-A separation of V(H)3 Fab from Fc after papain digestion of antibodies. J Biomol Tech 2011; 22: 50-2.
24. Petrakis I, Mavroeidi V, Stylianou K, Giannakakis K, DaphnisE. Blocking glomerular immunoglobulin deposits in a mouse model of lupus nephritis on indirect immunofluorescence with the use of Fab fragments. J Immunol Methods 2011; 376(1-2): 139-42.
25. Mangin PH, Tang C, Bourdon C, et al. A humanized GPVImouse model to assess the antithrombotic efficacy of anti- GPVI agents. J Pharmacol Exp Ther 2012; 341(1): 156-63.
26. Hamoudi H, Sorensen TL. Effect of intravitreal ranibizumab inthe treatment of peripapillary choroidal neovascularisation. J Ophthalmol 2011; 2011: 602729.
27. Lee FL, Kwon OW, Chung H, Lai CC, Sheu SJ, Yoon YH.Ranibizumab in South Korean and Taiwanese patients with age-related macular degeneration: primary outcome of the EXTEND 3 study. Acta Ophthalmol 2012; [Epub ahead of print].
28. Kaushik VV, Moots RJ. CDP-870 (certolizumab) in rheumatoidarthritis. Expert Opin Biol Ther 2005; 5: 601-6.
29. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumabpegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
30. Goel N, Stephens S. Certolizumab pegol. MAbs 2010; 2: 137-47.
31. Peterson E, Owens SM, Henry RL. Monoclonal antibody formand function: manufacturing the right antibodies for treating drug abuse. AAPS J 2006; 8: E383-90.
32. Arafat WO, Gomez-Navarro J, Buchsbaum DJ, et al. Effectivesingle chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther 2002; 9: 256-62.
33. Le Gall F, Kipriyanov SM, Moldenhauer G, Little M. Di-, tri- andtetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett 1999; 453: 164-8.
34. Adams GP, Schier R, McCall AM, et al. Prolonged in vivotumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998; 77: 1405-12.
35. Mathew JP, Shernan SK, White WD, et al. Preliminary reportof the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. Stroke 2004; 35: 2335-9.
36. Testa L, Van Gaal WJ, Bhindi R, et al. Pexelizumab inischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg 2008; 136: 884-93.
37. Reichert JM. Antibody-based therapeutics to watch in 2011.MAbs 2011; 3: 76-99.
38. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form ofTNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53: 45-53.
39. Reichert JM. Antibodies to watch in 2010. MAbs 2010; 2: 84-100.
40. Nelson AL, Dhimolea E, Reichert JM. Development trends forhuman monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9: 767-74.
41. Ramiro S, Radner H, van der Heijde D, et al. Combinationtherapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011;(10): CD008886.
42. Klipa D, Mahmud N, Ahsan N. Antibody immunosuppressivetherapy in solid organ transplant: Part II. MAbs 2010; 2: 607-12.
43. Davis JS, Currie BJ, Fisher DA, et al. Prevention ofopportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory. Commun Dis Intell 2003; 27: 526-32.
44. McMahan CJ, Slack JL, Mosley B, et al. A novel IL-1 receptor,cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 1991; 10: 2821-32
45. Ohsugi Y. Recent advances in immunopathophysiology ofinterleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull 2007; 30: 2001-6.
46. Elliott M, Benson J, Blank M, et al. Ustekinumab: lessonslearned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann NY Acad Sci 2009; 1182: 97-110.
47. Berard JL, Velez RL, Freeman RB, Tsunoda SM. A review ofinterleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy 1999; 19: 1127-37.
48. Sgro C. Side-effects of a monoclonal antibody, muromonabCD3/orthoclone OKT3: bibliographic review. Toxicology 1995; 105: 23-29.
49. Wilde MI, Goa KL. Muromonab CD3: a reappraisal of itspharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 1996; 51: 865-94.
50. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized,Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala- Ala) in the treatment of acute renal allograft rejection. Transplantation 1999; 68: 608-16.
51. Wiseman LR, Faulds D. Daclizumab: a review of its use in theprevention of acute rejection in renal transplant recipients. Drugs 1999; 58: 1029-42.
52. Calmus Y. [Immunosuppression after liver transplantation].Presse Med 2009; 38: 1307-13.
53. Ramirez CB, Marino IR. The role of basiliximab inductiontherapy in organ transplantation. Expert Opin Biol Ther 2007; 7: 137-48.
54. McKeage K, McCormack PL. Basiliximab: a review of its useas induction therapy in renal transplantation. BioDrugs 2010; 24: 55-76.
55. Goldsmith SJ, Signore A. An overview of the diagnostic andtherapeutic use of monoclonal antibodies in medicine. Q J Nucl Med Mol Imaging 2010; 54: 574-81.
56. Antoniu SA. Daclizumab: a potential asthma therapy? RecentPat Inflamm Allergy Drug Discov 2010; 4: 214-21.
57. Deng CY, Qi H, Wang XG, Zhou HX, Deng SP, Li FR. Role ofT and dendritic cells in mouse islet allografts treated with anti- CD45RB monoclonal antibodies. Transplant Proc 2011; 43: 2721-7.
58. Gagliani N, Gregori S, Jofra T, et al. Rapamycin combined withanti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation. PLoS One 2011; 6: e28434.
59. Setoguchi K, Schenk AD, Ishii D, et al. LFA-1 antagonisminhibits early infiltration of endogenous memory CD8 T cells into cardiac allografts and donor-reactive T cell priming. Am J Transplant 2011; 11: 923-35.
60. Cretolle-Vastel C, Camby C, Cerf-Bensussan N, et al. [Role ofcalcineurin-dependent drugs on the immunosuppressive effect induced by the anti-LFA-1 antibody in a fetal intestinal transplantation model in mice]. Chirurgie 1999; 124: 503-10.
61. Gaguski ME, Karcheski T. Dosing done right: a review ofcommon chemotherapy calculations. Clin J Oncol Nurs 2011; 15: 471-3.
62. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodiesfor the treatment of cancer. Semin Cancer Biol 2012; 22(1): 3-13.
63. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted,monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010; 28: 4390-9.
64. Scott SD. Rituximab: a new therapeutic monoclonal antibodyfor non-Hodgkin's lymphoma. Cancer Pract 1998; 6: 195-7.
65. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8(Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95.
66. Saini KS, Azim HA Jr, Cocorocchio E, et al. Rituximab inHodgkin lymphoma: is the target always a hit? Cancer Treat Rev 2011; 37: 385-90.
67. Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecularmechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci 2011; 16: 277-306.
68. Tedder TF, Forsgren A, Boyd AW, Nadler LM, SchlossmanSF. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol 1986; 16: 881-7.
69. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer.Nat Rev Cancer 2012; 12: 278-87.
70. Dillman RO, Hendrix CS. Unique aspects of supportive careusing monoclonal antibodies in cancer treatment. Support Cancer Ther 2003; 1: 38-48.
71. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 byanti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002; 51: 15-24.
72. Nishida M, Teshigawara K, Niwa O, et al. Novel humanizedanti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions. Int J Oncol 2008; 32: 1263-74.
73. Stein R, Qu Z, Chen S, et al. Characterization of a newhumanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004; 10: 2868-78.
74. Robak T, Robak E. New anti-CD20 monoclonal antibodies forthe treatment of B-cell lymphoid malignancies. BioDrugs 2011; 25: 13-25.
75. Reichert JM, Dhimolea E. The future of antibodies as cancerdrugs. Drug Discov Today 2012; [Epub ahead of print].
76. O'Mahony D, Bishop MR. Monoclonal antibody therapy. FrontBiosci 2006; 11: 1620-35.
77. Wang SC, Hung MC. HER2 overexpression and cancertargeting. Semin Oncol 2001; 28: 115-24.
78. Wang SC, Zhang L, Hortobagyi GN, Hung MC. TargetingHER2: recent developments and future directions for breast cancer patients. Semin Oncol 2001; 28: 21-9.
79. Berns EM, Foekens JA, van Putten WL, et al. Prognosticfactors in human primary breast cancer: comparison of c-myc and HER2/neu amplification. J Steroid Biochem Mol Biol 1992; 43: 13-9.
80. Hancock MC, Langton BC, Chan T, et al. A monoclonalantibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991; 51: 4575-80.
81. Vrdoljak E, Boban M, Ban M. Lapatinib in the treatment ofHER-2 overexpressing breast cancer. J BUON 2011; 16: 393-9.
82. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib withtrastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379(9816): 633-40.
83. Hysing J, Wist E. Cardiotoxic effects of trastuzumab. TidsskrNor Laegeforen 2011; 131: 2239-41.
84. McDonagh CF, Huhalov A, Harms BD, et al. Antitumor activityof a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11(3): 582-93.
85. Robinson MK, Hodge KM, Horak E, et al. Targeting ErbB2 andErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99: 1415-25.
86. Leahy DJ. A molecular view of anti-ErbB monoclonal antibodytherapy. Cancer Cell 2008; 13: 291-3.
87. Fang L, Barekati Z, Zhang B, Liu Z, Zhong X. Targeted therapyin breast cancer: what's new? Swiss Med Wkly 2011; 141: w13231.
88. Groth A, Salnikov AV, Ottinger S, et al. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting. Clin Cancer Res 2012; 18: 1028-38.
89. Nagorsen D, Baeuerle PA. Immunomodulatory therapy ofcancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011; 317: 1255-60.
90. Kontermann R. Dual targeting strategies with bispecificantibodies. MAbs 2012; 4: [Epub ahead of print].
91. Wang-Johanning F, Rycaj K, Plummer JB, et al.Immunotherapeutic Potential of Anti-Human EndogenousCurrent and Experimental Antibody-Based TherapeuticsRetrovirus-K Envelope Protein Antibodies in Targeting Breast Tumors. J Natl Cancer Inst 2012; 104(3): 189-210.
92. Miyazono K. TGF-beta receptors and signal transduction. Int JHematol 1997; 65: 97-104.
93. Leung K. 89Zr-Desferrioxamine-anti-CD105 TRC105 chimericmonoclonal antibody. In: ed. ^Eds. Molecular Imaging and Contrast Agent Database (MICAD): Bethesda MD 2004.
94. Schrag D. The price tag on progress--chemotherapy forcolorectal cancer. N Engl J Med 2004; 351: 317-9.
95. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil,leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-71.
96. Nguyen A, Hoang V, Laquer V, Kelly KM. Angiogenesis incutaneous disease: part I. J Am Acad Dermatol 2009; 61: 921-42; quiz 943-4.
97. Kawazoe Y, Hatake K, Suenaga M, Mizunuma N. [Administration-limiting factor of bevacizumab for patient with metastatic colorectal cancer]. Nihon Rinsho 2011; 69 Suppl 3: 472-6.
98. Bruera G, Cannita K, Giuliante F, et al. Effectiveness of LiverMetastasectomies in Patients With Metastatic Colorectal Cancer Treated With FIr-B/FOx Triplet Chemotherapy Plus Bevacizumab. Clin Colorectal Cancer 2011; 11(2): 119-26.
99. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added toneoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366: 310-20.
100. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309.
101. Croom KF, Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 2011; 71: 2213-29.
102. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 2010; 1: 497-514.
103. Schafer AI. Antiplatelet therapy. Am J Med 1996; 101: 199-209.
104. nd. Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med 1988; 319: 689-98.
105. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991; 83: 143-144.
106. Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci 1989; 10: 453-8.
107. Scharf RE, Rahman MM, Seidel H. The impact and management of acquired platelet dysfunction. Hamostaseologie 2011; 31: 28-40.
108. Rivera J, Lozano ML, Navarro-Nunez L, Vicente V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 2009; 94: 700-11.
109. Jackson SP, Nesbitt WS, Westein E. Dynamics of platelet thrombus formation. J Thromb Haemost 2009; 7 Suppl 1: 17-20.
110. Kanaji S, Kuether EL, Fahs SA, et al. Correction of Murine Bernard-Soulier Syndrome by Lentivirus-mediated Gene Therapy. Mol Ther 2011; 20(3): 625-32.
111. Vettore S, Tezza F, Malara A, et al. A A386G biallelic GPIbalpha gene mutation with anomalous behavior: a new mechanism suggested for Bernard-Soulier syndrome pathogenesis. Haematologica 2011; 96: 1878-82.
112. Shenkman B, Livnat T, Misgav M, Budnik I, Einav Y, Martinowitz U. The in vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann's thrombasthenia. Platelets 2012; [Epub ahead of print].
113. Lobo V, Shetty S, Kulkarni B, Ghosh K. A novel ELISA for diagnosis of Glanzmann's thrombasthenia and the heterozygote carriers. Ann Hematol 2011; 91(6): 917-21.
114. Deckmyn H, Vanhoorelbeke K, Peerlinck K. Inhibitory andactivating human antiplatelet antibodies. Baillieres Clin Haematol 1998; 11: 343-59.
115. Lajus S, Clofent-Sanchez G, Jais C, Coste P, Nurden P, Nurden A. Thrombocytopenia after abciximab use results from different mechanisms. Thromb Haemost 2010; 103: 651-61.
116. Watson TD, Stark JE, Vesta KS. Pantoprazole-induced thrombocytopenia. Ann Pharmacother 2006; 40: 758-61.
117. Eitel I, Desch S, Schindler K, Fuernau G, Schuler G, Thiele H. Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction. Int J Cardiol 2011; 153: 21-5.
118. Kemshead JT, Hopkins K. Uses and limitations of monoclonal antibodies (MoAbs) in the treatment of malignant disease: a review. J R Soc Med 1993; 86: 219-24.
119. Nakamura T, Kambayashi J, Okuma M, Tandon NN. Activation of the GP 2b-3a complex induced by platelet adhesion to collagen is mediated by both alpha(2)beta(1) integrin and GP VI. J Biol Chem 1999; 274: 11897-903.
120. Beer JH, Rabaglio M, Berchtold P, et al. Autoantibodies against the platelet glycoproteins (GP) IIb/IIIa, Ia/IIa, and IV and partial deficiency in GPIV in a patient with a bleeding disorder and a defective platelet collagen interaction. Blood 1993; 82: 820-9.
121. Boylan B, Berndt MC, Kahn ML, Newman PJ. Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti- human platelet agents. Blood 2006; 108: 908-14.
122. Hers I, Berlanga O, Tiekstra MJ, Kamiguti AS, Theakston RD, Watson SP. Evidence against a direct role of the integrin alpha2beta1 in collagen-induced tyrosine phosphorylation in human platelets. Eur J Biochem 2000; 267: 2088-97.
123. Lecut C, Feeney LA, Kingsbury G, et al. Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. J Thromb Haemost 2003; 1: 2653-62.
124. Ohlmann P, Hechler B, Ravanat C, et al. Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression. J Thromb Haemost 2008; 6: 1003-11.
125. Li H, Lockyer S, Concepcion A, et al. The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. Arterioscler Thromb Vasc Biol 2007; 27: 1199-205.
126. Kleinschnitz C, De Meyer SF, Schwarz T, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood 2009; 113: 3600-3603.
127. Wadanoli M, Sako D, Shaw GD, et al. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Haemost 2007; 98: 397-405.
128. Kageyama S, Yamamoto H, Nakazawa H, Yoshimoto R. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res 2001; 101: 395-404.
129. Kageyama S, Matsushita J, Yamamoto H. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur J Pharmacol 2002; 443: 143-9.
130. Wu D, Vanhoorelbeke K, Cauwenberghs N, et al. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood 2002; 99: 3623-8.
131. Dai K, Zhu H, Ruan C. Generation and characterization ofrecombinant single chain Fv antibody that recognizes platelet glycoprotein Ibalpha. Thromb Res 2003; 109: 137-44.
132. Ramage AG, Villalon CM. 5-hydroxytryptamine andcardiovascular regulation. Trends Pharmacol Sci 2008; 29: 472-81.
133. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derivedserotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208: 961-72.
134. Verdot L, Ferrer-di-Martino M, Hoebeke J. Immunogenic andantigenic analysis of the extracellular loops of the serotoninergic 5-HT1A receptor. Blood Press Suppl 1996; 3: 8-10.
135. Verdot L, Bertin B, Guilloteau D, Strosberg AD, Hoebeke J.Characterization of pharmacologically active anti-peptide antibodies directed against the first and second extracellular loops of the serotonin 5-HT1A receptor. J Neurochem 1995; 65: 319-28.
136. Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK.Biochemical characterization of PECAM-1 (CD31 antigen) on human platelets. Thromb Haemost 1991; 66: 700-7.
137. DeLisser HM, Yan HC, Newman PJ, Muller WA, Buck CA, Albelda SM. Platelet/endothelial cell adhesion molecule-1 (CD31)-mediated cellular aggregation involves cell surface glycosaminoglycans. J Biol Chem 1993; 268: 16037-46.
138. DeLisser HM, Newman PJ, Albelda SM. Platelet endothelialcell adhesion molecule (CD31). Curr Top Microbiol Immunol 1993; 184: 37-45.
139. Newman PJ. The role of PECAM-1 in vascular cell biology.Ann NY Acad Sci 1994; 714: 165-74.
140. Piali L, Albelda SM, Baldwin HS, Hammel P, Gisler RH, Imhof BA. Murine platelet endothelial cell adhesion molecule (PECAM-1)/CD31 modulates beta 2 integrins on lymphokine activated killer cells. Eur J Immunol 1993; 23: 2464-71.
141. Jones CI, Moraes LA, Gibbins JM. Regulation of plateletbiology by platelet endothelial cell adhesion molecule-1. Platelets 2011;23(5): 331-5.
142. Valentini X, Gossiaux A, Caron N, Nonclercq D, Legrand A, Toubeau G. Monoclonal antibody to CD31 (PECAM-1) inhibits tubular regeneration after ischemia reperfusion injury in the rat. Nephron Exp Nephrol 2011; 118: e60-8.
143. Brister SJ, Buchanan MR. Aspirin "resistance" and its impacton cardiovascular morbidity and mortality: it is real, clinically relevant and should be measured. Heart 2009; 95: 1223-4.
144. Parise LV, Venton DL, Le Breton GC. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction. J Pharmacol Exp Ther 1984; 228: 240-4.
145. Parise LV, Venton DL, Le Breton GC. ThromboxaneA2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP. J Pharmacol Exp Ther 1982; 222: 276-81.
146. Pollock WK, Armstrong RA, Brydon LJ, Jones RL, MacIntyreDE. Thromboxane-induced phosphatidate formation in human platelets. Relationship to receptor occupancy and to changes in cytosolic free calcium. Biochem J 1984; 219: 833-42.
147. Brace LD, Venton DL, Le Breton GC. Reversal of thromboxaneA2/prostaglandin H2 and ADP-induced calcium release in intact platelets. Am J Physiol 1985; 249: H8-13.
148. Brace LD, Venton DL, Le Breton GC. ThromboxaneA2/prostaglandin H2 mobilizes calcium in human blood platelets. Am J Physiol 1985; 249: H1-7.
149. Bailey JM, Prostaglandins, leukotrienes, and lipoxins:biochemistry, mechanism of action, and clinical applications. Plenum Press: New York 1985.
150. Murad JP, Espinosa EV, Ting HJ, Khasawneh FT. The C-terminal segment of the second extracellular loop of the thromboxane A2 receptor plays an important role in platelet aggregation. Biochem Pharmacol 2012; 83: 88-96.
151. Murad JP, Espinosa EV, Ting HJ, Khasawneh FT.Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan. J Cardiovasc Pharmacol Ther 2012; 17: 308-14.
152. Bross PF, Beitz J, Chen G, et al. Approval summary:gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490-6.
153. Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumabozogamicin, a potent and selective anti-CD33 antibody calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002; 13: 47-58.
154. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg(gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92: 406-13.
155. Wadleigh M, Richardson PG, Zahrieh D, et al. Priorgemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578-82.
156. Casi G, Neri D. Antibody-drug conjugates: Basic concepts,examples and future perspectives. J Control Release 2012; 161(2): 422-8.
157. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX.Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2 positive cancer. Clin Cancer Res 2011; 17: 6437-47.
158. Awada A, Bozovic-Spasojevic I, Chow L. New therapies inHER2-positive breast cancer: A major step towards a cure of the disease? Cancer Treat Rev 2012; 38(5): 494-504.
159. Gualberto A. Brentuximab Vedotin (SGN-35), an antibody-drugconjugate for the treatment of CD30-positive malignancies. Expert Opin Investig Drugs 2012; 21: 205-16.
160. Furtado M, Rule S. Emerging Pharmacotherapy for Relapsedor Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin. Clin Med Insights Oncol 2012; 6: 31-9.
161. Murphy EA, Majeti BK, Mukthavaram R, Acevedo LM, Barnes LA, Cheresh DA. Targeted nanogels: a versatile platform for drug delivery to tumors. Mol Cancer Ther 2011; 10: 972-82.
162. Fay F, McLaughlin KM, Small DM, et al. Conatumumab (AMG655) coated nanoparticles for targeted pro-apoptotic drug delivery. Biomaterials 2011; 32: 8645-53.
163. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapycomes of age. J Clin Oncol 2011; 29: 4828-36.
164. Byrne WL, Mills KH, Lederer JA, O'Sullivan GC. Targetingregulatory T cells in cancer. Cancer Res 2011; 71: 6915-20.
165. Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-TargetedAntitumor Immunotherapy. Cancer Res 2011; 71: 6567-71.
166. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011; 71: 3540-51.
167. Weber J. Immune checkpoint proteins: a new the rapeuticparadigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37: 430-9.
168. Lape M, Paula S, Ball WJ, Jr. A molecular model for cocainebinding by the immunotherapeutic human/mouse chimeric monoclonal antibody 2E2. Eur J Med Chem 2010; 45: 2291-8.
169. Heinemann L, Pfutzner A, Heise T. Alternative routes ofadministration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001; 7: 1327-51.
170. Becquemin MH, Chaumuzeau JP. Inhaled insulin: a model forpulmonary systemic absorption? Rev Mal Respir 2010; 27: e54-65.
171. Perusiova J. [Insulin therapy in 2011]. Vnitr Lek 2011; 57: 930-6.